Bullfrog AI Holdings (Bullfrog AI Holdings) ROCE % : -161.84% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Bullfrog AI Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bullfrog AI Holdings's annualized ROCE % for the quarter that ended in Mar. 2024 was -161.84%.

Bullfrog AI Holdings ROCE % Historical Data

The historical data trend for Bullfrog AI Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bullfrog AI Holdings ROCE % Chart

Bullfrog AI Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

Bullfrog AI Holdings Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial								-646.23	-123.48	-115.08	-162.84	-161.84

Bullfrog AI Holdings ROCE % Calculation

Bullfrog AI Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-5.277	/	( ( (0.08 - 3.138)	+	(2.777 - 0.184) )	/ 2 )
	=	-5.277	/	( (-3.058	+	2.593)	/ 2 )
	=	-5.277	/	-0.2325
	=	2,269.68 %

Bullfrog AI Holdings's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-7.604	/	( ( (2.777 - 0.184)	+	(7.649 - 0.845) )	/ 2 )
	=	-7.604	/	( ( 2.593	+	6.804 )	/ 2 )
	=	-7.604	/	4.6985
	=	-161.84 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Bullfrog AI Holdings (NAS:BFRG) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bullfrog AI Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Bullfrog AI Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bullfrog AI Holdings (Bullfrog AI Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Bullfrog AI Holdings Inc (NAS:BFRG) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

325 Ellington Boulevard, Unit 317, Gaithersburg, MD, USA, 20878

Website

https://www.bullfrogai.com

Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.

Executives

William Enright	director	910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
R Don Elsey	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Dane R Saglio	officer: Chief Financial Officer
Jason David Hanson	director	8125 NORTH HAYDEN ROAD, SCOTTSDALE AZ 85258-2463
Vininder Singh	director, 10 percent owner, officer: Chief Executive Officer	4 BLACK KETTLE COURT, BOYDS MD 20841